The role of ruxolitinib in the management of acute GVHD

Basit Öğe Kaydı
dc.contributor.authorNamdaroglu, Sinem
dc.contributor.authorHidayet, Emine
dc.contributor.authorAydin, Muruvvet Seda
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorBerber, Ilhami
dc.contributor.authorCinar, Olgu Erkin
dc.contributor.authorOzet, Gulsum
dc.date.accessioned2026-04-04T13:34:50Z
dc.date.available2026-04-04T13:34:50Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground and objectives: Following an allogeneic hematopoietic stem cell transplant (allo-HSCT), a primary cause of morbidity and mortality is still steroid-refractory acute graft-versus-host disease (SR-aGVHD). Recently, ruxolitinib, an oral inhibitor of JAK1 and JAK2, was approved for use in individuals suffering from SR-aGVHD. This study aimed to analyze the efficacy and toxicity of ruxolitinib in the real world. Material and methods: In the present study, we investigated the effectiveness and toxicity of ruxolitinib in patients with SR-aGVHD using a multicenter retrospective analysis. We enrolled 23 patients between 2018 and 2024 who received ruxolitinib treatment for SR-aGVHD. Results: The first response was acheived in a median of 28 days (range, 12-150). The overall response rate (ORR) for ruxolitinib therapy was 43.5% (10/23) after one month and 61 % (14/23) after two months, respectively. The median overall survival was 69 months. Reactivation of cytomegalovirus (26.1 %) and grade 3-4 anemia (30.4 %) were the two main side effects of ruxolitinib therapy. Seven patients (30.4 %) passed away following a follow-up of a median of six months (range 1-70). The reasons for death included sepsis (n = 2, 28.6 %), progression of aGVHD (n = 3, 42.8 %), and other reasons. Conclusion: Ruxolitinib has an ORR of 61 % for SR-aGVHD, making it a safe and effective therapy choice in realworld settings.
dc.identifier.doi10.1016/j.transci.2024.104055
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue1
dc.identifier.orcid0000-0001-6872-3780
dc.identifier.orcid0000-0002-7222-499X
dc.identifier.orcid0000-0002-3285-417X
dc.identifier.orcid0000-0003-3312-8476
dc.identifier.pmid39719750
dc.identifier.scopus2-s2.0-85212845410
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.transci.2024.104055
dc.identifier.urihttps://hdl.handle.net/11616/109408
dc.identifier.volume64
dc.identifier.wosWOS:001394342800001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofTransfusion and Apheresis Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectGraft versus host disease
dc.subjectRuxolitinib
dc.subjectJAK inhibitor
dc.subjectSteroids
dc.subjectHematopoietic stem cell transplantation
dc.titleThe role of ruxolitinib in the management of acute GVHD
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu